JP2010527331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527331A5 JP2010527331A5 JP2010506698A JP2010506698A JP2010527331A5 JP 2010527331 A5 JP2010527331 A5 JP 2010527331A5 JP 2010506698 A JP2010506698 A JP 2010506698A JP 2010506698 A JP2010506698 A JP 2010506698A JP 2010527331 A5 JP2010527331 A5 JP 2010527331A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- modulator
- disorder
- adp receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 claims 7
- 108010085249 Purinergic P2 Receptors Proteins 0.000 claims 7
- 229940075993 receptor modulator Drugs 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims 4
- 229950004274 ifetroban Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 2
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical group C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 claims 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010072563 Peripheral artery stenosis Diseases 0.000 claims 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000005485 Thrombocytosis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- KVLRBRZHCOVMNX-IDTAVKCVSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical group C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KVLRBRZHCOVMNX-IDTAVKCVSA-N 0.000 claims 1
- GAORIKFOSRGMEL-WOUKDFQISA-N [(2r,3s,4r,5r)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C12=NC(SCCC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O GAORIKFOSRGMEL-WOUKDFQISA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960001006 picotamide Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229960004197 prasugrel Drugs 0.000 claims 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229950004496 ramatroban Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- XUTLOCQNGLJNSA-RGVLZGJSSA-N terbogrel Chemical compound CC(C)(C)\N=C(/NC#N)NC1=CC=CC(C(=C/CCCC(O)=O)\C=2C=NC=CC=2)=C1 XUTLOCQNGLJNSA-RGVLZGJSSA-N 0.000 claims 1
- 229950006665 terbogrel Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005001 ticlopidine Drugs 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical group ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
- -1 α-cyclopropylcarbonyl-2-fluorobenzyl Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91578407P | 2007-05-03 | 2007-05-03 | |
| US91578507P | 2007-05-03 | 2007-05-03 | |
| US94728907P | 2007-06-29 | 2007-06-29 | |
| US94731607P | 2007-06-29 | 2007-06-29 | |
| PCT/US2008/062565 WO2008137791A1 (en) | 2007-05-03 | 2008-05-02 | Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527331A JP2010527331A (ja) | 2010-08-12 |
| JP2010527331A5 true JP2010527331A5 (enExample) | 2011-06-23 |
Family
ID=39943967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506698A Pending JP2010527331A (ja) | 2007-05-03 | 2008-05-02 | Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用 |
| JP2010506700A Pending JP2010526104A (ja) | 2007-05-03 | 2008-05-02 | トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506700A Pending JP2010526104A (ja) | 2007-05-03 | 2008-05-02 | トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090012115A1 (enExample) |
| EP (2) | EP2144999A4 (enExample) |
| JP (2) | JP2010527331A (enExample) |
| KR (2) | KR20100037029A (enExample) |
| CN (2) | CN101711279A (enExample) |
| AU (2) | AU2008247439A1 (enExample) |
| CA (2) | CA2688319A1 (enExample) |
| IL (2) | IL201885A0 (enExample) |
| MX (2) | MX2009011745A (enExample) |
| WO (2) | WO2008137793A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100168137A1 (en) * | 2006-12-20 | 2010-07-01 | Johan Raud | Combination for use in the treatment of inflammatory disorders |
| WO2008087371A1 (en) * | 2007-01-16 | 2008-07-24 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
| KR20130026504A (ko) * | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
| US10016417B2 (en) | 2011-11-07 | 2018-07-10 | Diakron Pharmaceuticals, Inc. | Extended release formulation of a direct thrombin inhibitor |
| JP6183459B2 (ja) * | 2012-08-06 | 2017-08-23 | Jnc株式会社 | 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験 |
| US12161632B2 (en) | 2014-05-16 | 2024-12-10 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
| JP6273072B2 (ja) * | 2014-05-16 | 2018-01-31 | カンバーランド ファーマシューティカルズ，インコーポレーテッド | イフェトロバンにより心臓線維症を治療する組成物及び方法 |
| ES2984026T3 (es) * | 2015-06-16 | 2024-10-28 | Atxa Therapeutics Ltd | Antagonistas del receptor de tromboxano |
| KR102448406B1 (ko) * | 2015-06-30 | 2022-09-27 | 큠버랜드 파마슈티컬즈 인코포레이티드 | Ａｅｒｄ/천식에서 트롬복산 수용체 길항제 |
| EP3454850B1 (en) | 2016-05-11 | 2023-06-21 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists |
| AU2021246444A1 (en) * | 2020-03-31 | 2022-10-20 | Martin Ogletree | Methods and pharmaceutical compositions of thromboxane A2 receptor antagonist for the treatment of COVID-19 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895115A (en) * | 1974-03-01 | 1975-07-15 | Serono Ist Farm | Method of inhibiting platelet aggregation |
| US5071866A (en) * | 1989-07-31 | 1991-12-10 | Bristol-Myers Squibb Company | Arylpyrazole derivatives as anti-platelet agents |
| US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US5605917A (en) * | 1994-12-22 | 1997-02-25 | Bristol-Myers Squibb Company | Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| JP2005533830A (ja) * | 2002-07-09 | 2005-11-10 | ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ | トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ |
| WO2006066008A2 (en) * | 2004-12-14 | 2006-06-22 | Portola Pharmaceuticals, Inc. | Device and methods for identifying and treating aspirin non-responsive patients |
| US7381536B2 (en) * | 2005-03-01 | 2008-06-03 | Gurbel Paul A | Assessment of cardiac health and thrombotic risk in a patient |
-
2008
- 2008-05-02 AU AU2008247439A patent/AU2008247439A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062567 patent/WO2008137793A1/en not_active Ceased
- 2008-05-02 KR KR1020097025330A patent/KR20100037029A/ko not_active Withdrawn
- 2008-05-02 MX MX2009011745A patent/MX2009011745A/es not_active Application Discontinuation
- 2008-05-02 KR KR1020097025329A patent/KR20100032854A/ko not_active Withdrawn
- 2008-05-02 EP EP08747593A patent/EP2144999A4/en active Pending
- 2008-05-02 CA CA002688319A patent/CA2688319A1/en not_active Abandoned
- 2008-05-02 MX MX2009011744A patent/MX2009011744A/es not_active Application Discontinuation
- 2008-05-02 JP JP2010506698A patent/JP2010527331A/ja active Pending
- 2008-05-02 AU AU2008247441A patent/AU2008247441A1/en not_active Abandoned
- 2008-05-02 CN CN200880014605A patent/CN101711279A/zh active Pending
- 2008-05-02 US US12/114,642 patent/US20090012115A1/en not_active Abandoned
- 2008-05-02 EP EP08747595A patent/EP2146573A4/en not_active Withdrawn
- 2008-05-02 JP JP2010506700A patent/JP2010526104A/ja active Pending
- 2008-05-02 CA CA002688317A patent/CA2688317A1/en not_active Abandoned
- 2008-05-02 CN CN200880019332A patent/CN101686668A/zh active Pending
- 2008-05-02 US US12/114,646 patent/US20090012136A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062565 patent/WO2008137791A1/en not_active Ceased
-
2009
- 2009-11-02 IL IL201885A patent/IL201885A0/en unknown
- 2009-11-02 IL IL201886A patent/IL201886A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cattaneo et al. | Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance | |
| Van Giezen et al. | Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis | |
| ES2895128T3 (es) | Derivados de 2-hidroxi-tetrahidrotienopiridina ópticamente activos, procedimiento de preparación y utilización en la elaboración de un medicamento de los mismos | |
| Chaudhary et al. | Biological diversity of thiophene: a review | |
| KR101502588B1 (ko) | 클로피도그렐 및 아스피린의 복합제제 | |
| US20090012136A1 (en) | Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists | |
| CA2808520C (en) | Methods for the treatment or prophylaxis of thrombosis or embolism | |
| KR101675501B1 (ko) | 클로피도그렐 및 아스피린의 복합제제 | |
| JP2001519391A (ja) | 新規な組み合わせ物 | |
| PT1797099E (pt) | Compostos de piperidinilamino-tieno[2,3-d]pirimidina | |
| Costopoulos et al. | Novel oral anticoagulants in acute coronary syndrome | |
| WO2006099217A3 (en) | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent | |
| HUP0400818A2 (hu) | Tieno[2,3-d]pirimidinek alkalmazása és az ezeket tartalmazó gyógyszerkészítmények | |
| JP2010526104A5 (enExample) | ||
| KR101764785B1 (ko) | 약제학적 복합제제 | |
| Pudusseri et al. | A new paradigm shift in antithrombotic therapy | |
| Marcucci et al. | On-treatment platelet reactivity: state of the art and perspectives | |
| CA2848764A1 (en) | Controlled dosing of clopidogrel with gastric acid inhibition therapies | |
| Oqueli et al. | Clopidogrel resistance | |
| JP2002255814A5 (enExample) | ||
| Price | New antiplatelet therapies in development | |
| TW200407135A (en) | Medicinal compositions for anti-arteriosclerosis | |
| Savani et al. | A Review: Determination of Clopidogrel Bisulphate in Biological Fluid and Pharmaceutical Dosage Forms | |
| WO2014056418A1 (zh) | 含有阿斯匹林和维卡格雷的药用组合物 | |
| Nguyen et al. | A Prescriber's Guides to Oral Antiplatelet Therapy |